Study on the Clinical Efficacy of Teclistamab
Recruiting now
Conditions studied: Multiple Myeloma, Hematologic Diseases
In brief
The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA/CD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.
Key facts
- Study ID
- NCT06477783
- Run by
- Universitaire Ziekenhuizen KU Leuven
- People needed
- 100
- Starts
- 2024-12-01
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2025-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 years or older
- Written informed consent
- Has a diagnosis of relapsed and refractory multiple myeloma
- Has already received at least three previous treatments
- Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody
- Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria
- Anticipated to start treatment with teclistamab per routine clinical care or has started with teclistamab treatment ≤14 days before intended screening visit
You may not qualify if…
- Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program
- Has started teclistamab treatment >14 days before intended screening visit.
Where it is running
- UZ Leuven Gasthuisberg — Leuven, Belgium (enrolling)
- Universitair Ziekenhuis Antwerpen (UZA) — Edegem, Antwerpen, Belgium (enrolling)
- Grand Hôpital de Charleroi — Charleroi, Henegouwen, Belgium (enrolling)
- EpiCURA — Hornu, Henegouwen, Belgium (enrolling)
- CHU Ambroise Paré — Mons, Henegouwen, Belgium (enrolling)
- Jessa Ziekenhuis — Hasselt, Limburg, Belgium (enrolling)
- CHR Citadelle — Liège, Liège, Belgium (enrolling)
- CHU Liège — Liège, Liège, Belgium (enrolling)
- CHU UCL Namur — Yvoir, Namur, Belgium (enrolling)
- Algemeen Ziekenhuis Maria Middelares (AZMM) — Ghent, Oost-Vlaanderen, Belgium (enrolling)
- Universitair Ziekenhuis Gent (UZ Gent) — Ghent, Oost-Vlaanderen, Belgium (enrolling)
- Vitaz — Sint-Niklaas, Oost-Vlaanderen, Belgium (enrolling)
- Institut Jules Bordet — Brussels, Vlaams-Brabant, Belgium (enrolling)
- UCL Saint Luc — Brussels, Vlaams-Brabant, Belgium (enrolling)
- AZ Groeninge — Kortrijk, West-Vlaanderen, Belgium (enrolling)
- AZ Delta — Roeselare, West-Vlaanderen, Belgium (enrolling)
- Imelda — Bonheiden, Antwerpen, Belgium
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.